Daniel Rauh

You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect.
Schulz T, Gontla R, Teuber A, et al. (2025) Design, Synthesis, and SAR of Covalent KIT and PDGFRA Inhibitors─Exploring Their Potential in Targeting GIST. Journal of Medicinal Chemistry
Pervanidis KA, D'Angelo GD, Weisner J, et al. (2024) Akt Inhibitor Advancements: From Capivasertib Approval to Covalent-Allosteric Promises. Journal of Medicinal Chemistry. 67: 6052-6063
Grabe T, Jeyakumar K, Niggenaber J, et al. (2023) Addressing the Osimertinib Resistance Mutation EGFR-L858R/C797S with Reversible Aminopyrimidines. Acs Medicinal Chemistry Letters. 14: 591-598
Goebel L, Kirschner T, Koska S, et al. (2023) Targeting oncogenic KRasG13C with nucleotide-based covalent inhibitors. Elife. 12
Stehle J, Weisner J, Eichhorn L, et al. (2023) Insights into the Conformational Plasticity of the Protein Kinase Akt1 by Multi-Lateral Dipolar Spectroscopy. Chemistry (Weinheim An Der Bergstrasse, Germany). e202203959
Gehrtz P, Marom S, Bührmann M, et al. (2022) Optimization of Covalent MKK7 Inhibitors Crude Nanomole-Scale Libraries. Journal of Medicinal Chemistry
Lategahn J, Tumbrink HL, Schultz-Fademrecht C, et al. (2022) Insight into Targeting Exon20 Insertion Mutations of the Epidermal Growth Factor Receptor with Wild Type-Sparing Inhibitors. Journal of Medicinal Chemistry
van der Westhuizen L, Weisner J, Taher A, et al. (2022) Covalent allosteric inhibitors of Akt generated using a click fragment approach. Chemmedchem
Quambusch L, Depta L, Landel I, et al. (2021) Cellular model system to dissect the isoform-selectivity of Akt inhibitors. Nature Communications. 12: 5297
Niggenaber J, Heyden L, Grabe T, et al. (2020) Complex Crystal Structures of EGFR with Third-Generation Kinase Inhibitors and Simultaneously Bound Allosteric Ligands. Acs Medicinal Chemistry Letters. 11: 2484-2490